AI SummaryThe GLP-1 meal prep opportunity in India targets a rapidly growing obesity medication market expanding from ₹1,500 cr (2026) to ₹8,000 cr (2030). Users of semaglutide and similar drugs require specialized, low-calorie, high-protein nutrition support—a gap unfilled by existing packaged food brands. A subscription-based, direct-to-consumer meal prep business can capture 1–2M users by 2028, generating ₹500–1,200 cr in addressable market. Ideal for food entrepreneurs, MBAs in FMCG, and health-tech founders with logistics expertise, particularly in metro markets (Delhi-NCR, Bangalore, Mumbai, Hyderabad).
Loading...